Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity

Click to increase image sizeClick to decrease image size

Declaration of interest

C Blair is the co-founder of Disruptyx Therapeutics Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

We aknowledge DepMap Portal, a publicly available bioinformatic database, containing in-depth polyomic characterisation of a large heterogenous library of human cancer cell lines. Data from this database was yielded to support the narrative of the manuscript submitted.

Author contribution

C Blair wrote the article, analyzed the bioinformatic data and made the figures/tables.

S Cooke supported C Blair in writing the article and making the figures/tables.

Data availability statement

All data is available within article figures, tables and supplementary files.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737140.2024.2319035

Additional information

Funding

This paper was funded by the UK Research and Innovation > Medical Research Council [MR/X502807/1].